Literature DB >> 11901242

Cerebral amyloid angiopathy and vessel dysfunction.

Steven M Greenberg1.   

Abstract

Cerebral amyloid angiopathy (CAA), defined by deposition of the beta-amyloid peptide in medium and small cortical and meningeal vessels, is a well-recognized cause of hemorrhagic stroke. This paper reviews the accumulating evidence supporting an additional role for CAA in producing vessel dysfunction, reduced cerebral blood flow and ischemia. Ischemic lesions are characteristic of several hereditary CAA syndromes, including a recently described mutation of the amyloid precursor protein associated with dementia (but not hemorrhagic stroke) in an Iowa family. Ischemic lesions are seen in some sporadic CAA patients as well, and recent data from transgenic mice suggest potential mechanisms by which beta-amyloid may alter vessel physiology. Future studies will seek to define the clinical importance of vascular beta-amyloid as a potential target for drug therapy in dementia. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 11901242     DOI: 10.1159/000049149

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  27 in total

1.  Identification of neurovascular changes associated with cerebral amyloid angiopathy from subject-specific hemodynamic response functions.

Authors:  Rebecca J Williams; Bradley G Goodyear; Stefano Peca; Cheryl R McCreary; Richard Frayne; Eric E Smith; G Bruce Pike
Journal:  J Cereb Blood Flow Metab       Date:  2017-02-01       Impact factor: 6.200

2.  Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy.

Authors:  Ping Yan; Alec Zhu; Fan Liao; Qingli Xiao; Andrew Kraft; Ernie Gonzales; Ron Perez; Steven M Greenberg; David Holtzman; Jin-Moo Lee
Journal:  Stroke       Date:  2015-05-05       Impact factor: 7.914

3.  Cerebrovascular function in presymptomatic and symptomatic individuals with hereditary cerebral amyloid angiopathy: a case-control study.

Authors:  Anna M van Opstal; Sanneke van Rooden; Thijs van Harten; Eidrees Ghariq; Gerda Labadie; Panagiotis Fotiadis; M Edip Gurol; Gisela M Terwindt; Marieke J H Wermer; Mark A van Buchem; Steven M Greenberg; Jeroen van der Grond
Journal:  Lancet Neurol       Date:  2016-12-16       Impact factor: 44.182

Review 4.  Is apolipoprotein E4 an important risk factor for vascular dementia?

Authors:  Troy T Rohn
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Association of Cerebral Microbleeds With Cognitive Decline and Dementia.

Authors:  Saloua Akoudad; Frank J Wolters; Anand Viswanathan; Renée F de Bruijn; Aad van der Lugt; Albert Hofman; Peter J Koudstaal; M Arfan Ikram; Meike W Vernooij
Journal:  JAMA Neurol       Date:  2016-08-01       Impact factor: 18.302

6.  Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy.

Authors:  Y W Chen; M E Gurol; J Rosand; A Viswanathan; S M Rakich; T R Groover; S M Greenberg; E E Smith
Journal:  Neurology       Date:  2006-07-11       Impact factor: 9.910

7.  [Sporadic cerebral amyloid angiopathy with ischemic leukoencephalopathy and microbleeds. Cause for a rapidly progressive dementia syndrome].

Authors:  J Katchanov; G Bohner; M Könneker; U Kopp; K Izadpanah; E Larmann; R Klingebiel; F van Landeghem; F Masuhr; R Zschenderlein
Journal:  Nervenarzt       Date:  2005-10       Impact factor: 1.214

Review 8.  Multiphoton in vivo imaging of amyloid in animal models of Alzheimer's disease.

Authors:  Jinghui Dong; Raquel Revilla-Sanchez; Stephen Moss; Philip G Haydon
Journal:  Neuropharmacology       Date:  2010-04-14       Impact factor: 5.250

9.  Small vessel disease and subcortical vascular dementia.

Authors:  Raj N Kalaria; Timo Erkinjuntti
Journal:  J Clin Neurol       Date:  2006-03-20       Impact factor: 3.077

Review 10.  Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.

Authors:  Rawan Tarawneh; David M Holtzman
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-04       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.